Original text
Rate this translation
Your feedback will be used to help improve Google Translate
Home
Moonlake Immunotherapeutics
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
Jun 25 2023
4 min read

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

  • First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint
  • Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS
  • HiSCR50 met with 38 ppt delta vs placebo (p